Echocardiography is an essential non-invasive, accessible and reproducible technique, contributing to the correct assessment of cardiac structure and function in cardio-oncologic patients, both in the pre-oncologic treatment stage, during the oncological therapy course and after if necessary. Echocardiographic examinations of neoplastic patients are effective in early detection of “iatrogenic” cardiovascular dysfunctions, or, in case of pre-existing cardiovascular conditions, echocardiography is one of the most accessible and reliable tool to monitor these patients. Specific oncologic therapies may determine a wide range of cardiovascular effects, identified as “cancer-therapeutics-related cardiac dysfunction” (CTRCD): left ventricular dysfunction with all its underlying mechanisms, QT interval prolongation, hypertension, pulmonary hypertension, thromboembolic events, valvular dysfunctions, and pericardial disease (Moran and Plana, ASE’s comprehensive echocardiography, Elsevier, 2022). The risk-benefit assessment of cancer treatment led to the term “accepted cardiotoxicity”, defining those situations when cancer treatment may and should be given because its benefits are superior in comparison to a further possible cardiovascular impact (Lennep and Mitchell, Manualul Washington de Cardio-Oncologie. Ghid practic pentru diagnosticul si tratamentul complicatiilor cardiovasculare la pacientii cu cancer, Prior, 2024). Early cardio-protective therapy initiation (inhibitors of the renin-angiotensin-aldosterone system, beta-blockers) may reduce the risk of left ventricular dysfunction in patients receiving active oncologic therapy regimens (Fine and Mitchell, Manualul Washington de Cardio-Oncologie. Ghid practic pentru diagnosticul si tratamentul complicatiilor cardiovasculare la pacientii cu cancer, Prior, 2024).